AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects
Phase 1
Suspended
- Conditions
- Pharmacokinetics
- Interventions
- Drug: monophasic oral contraceptive
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00901290
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1550
- Registration Number
- NCT00901004
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
Phase 1
Completed
- Conditions
- NeoplasmsBreast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00900627
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
Asthma Control and Clinical Practice in Hungary 2009
Completed
- Conditions
- Asthma Control Level
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00900861
- Locations
- 🇭🇺
Research Site, Vasarosnameny, Hungary
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Co-administration of Saxagliptin and Metformin IR, FastedDrug: Saxagliptin/Metformin, FastingDrug: Co-administration of Saxagliptin and Metformin IR, FedDrug: Saxagliptin/Metformin, Fed
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00899470
- Locations
- 🇺🇸
Mds Pharma Services, Lincoln, Nebraska, United States
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00897390
- Locations
- 🇺🇸
Mds Pharma Services, Lincoln, Nebraska, United States
A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Other: Placebo
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00894322
- Locations
- 🇺🇸
Research Site, Lincoln, Nebraska, United States
Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease
Completed
- Conditions
- COPD
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00894426
- Locations
- 🇰🇷
Research Site, Pohang, Korea, Republic of
An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2009-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00892944
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
Completed
- Conditions
- GlycemiaHypertensionHyperlipidemia
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4045
- Registration Number
- NCT00891124
- Locations
- 🇰🇷
Research Site, Sungman, Korea, Republic of
🇰🇷Research SIte, Daegu, Korea, Republic of